The FDA has approved Itvisma (onasemnogene abeparvovec-brve) to treat children two years and older, teens, and adults living with spinal muscular atrophy (SMA). It is indicated for patients with a ...
Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated ...
A next-generation treatment from Novo Nordisk helped patients with diabetes lower their blood sugar and lose weight in a ...
The U.S. Food and Drug Administration has approved Itvisma as the first gene therapy for spinal muscular atrophy patients ...
Pharmaceutical Technology on MSN
Novartis secures approval from FDA for Itvisma to treat SMA
The approval is supported by findings from the open-label Phase IIIb STRENGTH study and the Phase III STEER study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback